Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat

Spironolactone (SPR), a mineralocorticoid receptor blocker, diminishes hyperglycemia-induced reduction in glucose-6-phosphate dehydrogenase (G6PD) activity, improving oxidative stress damage. This study investigated whether SPR ameliorates nephropathy by increasing G6PD activity and reducing oxidati...

Full description

Bibliographic Details
Main Authors: Bruno S Pessôa, Elisa BMI Peixoto, Alexandros Papadimitriou, Jacqueline M Lopes de Faria, José B Lopes de Faria
Format: Article
Language:English
Published: Hindawi - SAGE Publishing 2012-03-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1177/1470320311422581